LFST Q2: 26% Growth and 15% EBITDA Margins Make the Bull Case Harder to Ignore

Margin expansion is making the bull case harder to dismiss

LifeStance's easy "prove it" phase is shrinking. The company reported 26% revenue growth to $435.4 million, while adjusted EBITDA rose to $66.0 million from $34.0 million. Demand was rising at the same time: visits increased 19% to 2.6 million. Growing that quickly while also becoming more profitable is what makes this quarter stand out.

Management also reported 15% adjusted EBITDA margins and positive net income. That matters because the quarter was not just about top-line growth. LifeStance is starting to look less like a care network growing at any cost and more like a business that can turn demand into profit.

The market is already leaning that way. After the report, shares were trading at $10.89, near the top of the 52-week range of $3.81 to $11.76. Management also raised full-year revenue guidance to $1.685 billion to $1.725 billion and lifted adjusted EBITDA guidance to $215 million to $235 million.

The question is no longer whether LifeStance has demand. It does. The harder question is whether investors now need to pay up for a business that is converting that demand into margins.

Specialty services and center-level economics drove the quarter

The earlier results showed demand. This quarter showed the operating engine behind it.

Revenue per visit and center margins tell the story

Revenue per visit rose to $167, up 6% year over year, as management pointed to favorable payer contracting and mid-single-digit rate improvements. In plain English, LifeStance is not just filling schedules; it is getting better economics from the capacity it already has.

That matters more than it sounds. In outpatient care, even modest rate improvements can compound quickly when visit volume is large. When demand is strong and pricing improves, revenue can grow faster than fixed costs.

Management also said visit growth reflected improved clinician productivity and net clinician additions. The clinician base reached 8,542, up 11%. If demand is real and the staffing model is working, you should see fuller schedules and better utilization. That appears to be happening.

The clearest proof is still at the center level. Center margin reached $153 million, or 35.2% of revenue, which helped support the 15.2% adjusted EBITDA margin. That suggests the profit is coming from local unit economics first. Good center-level margins are the right kind of strength because they do not depend on valuation multiple expansion.

Hiring pace still has to coexist with productivity

The main operating risk is straightforward: if new hires slow schedules, slow documentation, or weaken patient flow, the margin story gets less convincing. LifeStance says productivity increased for a third consecutive quarter. If that continues, the model gets more credible.

There is also a near-term trade-off to watch. Management is investing in technology, marketing, and clinician compensation, and it has a new EHR system planned for 2027 that could create short-term productivity disruptions. For now, the operating engine looks solid. Over the next few quarters, the key question is whether productivity keeps improving or starts to stall under the weight of hiring and system changes.

The next test is whether the next leg holds

The bar is now more concrete. After a quarter of 26% revenue growth and 15% adjusted EBITDA margins, LifeStance is no longer asking investors to imagine the model works. It is asking them to underwrite the next leg. The company raised full-year revenue expectations to $1.685 billion to $1.725 billion and adjusted EBITDA expectations to $215 million to $235 million.

What bulls and bears are actually debating

Bulls have the cleaner case. Demand is still showing up in the core numbers: visits increased 19% to 2.6 million, the clinician base grew 11% to 8,542, and productivity increased for the third consecutive quarter.

Bears still have a fair question: is this quarter repeating, or is it a strong one-off? Part of the revenue quality still depends on favorable payer contracting and mid-single-digit rate improvements, and the clinician market remains competitive. If payer rates normalize or hiring gets tougher, profit expansion is less automatic.

What to watch next

Keep the scorecard simple. The key reality check is whether center-level strength holds after the guidance raise. Last quarter, center margin was $153 million, or 35.2% of revenue. The next question is whether that margin engine still looks healthy as the company pushes toward the higher full-year targets.

There is one more wrinkle to watch. Management's recent results were helped by strong clinician productivity and expansion in specialty services, while a new EHR system planned for 2027 could create short-term productivity disruptions. That is the kind of detail that can quietly change the next few quarters.

Because the stock is near the top of its 52-week range, the next attractive setup is more likely to require confirmation than hope.